Schivo and Partners Awarded €1.9m Disruptive Technologies Fund (DTIF) from Enterprise Ireland

 In News

Schivo as part of a consortium have been awarded the Disruptive Technologies Fund (DTIF) from Enterprise Ireland which is worth €1.9m over the course of the next three years.

The Disruptive Technologies Innovation Fund is a €500 million fund established under Project Ireland 2040 and is run by the Department of Business, Enterprise and Innovation with administrative support from Enterprise Ireland.

A medical device and life science manufacturing expert, Schivo are continuously involved in research and development to ensure that their customers will benefit from the most advanced technologies available. A dedicated engineering team will provide expertise in precision manufacturing, prototyping, surface finishing, wire EDM of manufactured parts and resurfacing of build plates.

“We are delighted to be part of this consortium and thank the government for their vision in establishing the Disruptive Technologies Innovation Fund,” said Graham Reeves, CEO of Schivo.  “New technologies present pathways and opportunities to radically improve patient outcomes and dramatically reduce the significant cost burdens within primary care and other treatment centres. We look forward to enhancing the strong additive manufacturing and coating technologies ecosystem within Ireland and the global opportunities this presents.”

The aim of the consortium is to further develop biodegradable implant technology in the orthopaedic sphere. The group will come together to further develop coatings technology for titanium (Ti) and magnesium (Mg) based medical devices for improving their osseointegration (bone to device connection) and to improve the surface quality of 3D metal printed implantable devices.

Disruptive Technology Fund Team

Schivo’s dedicated Disruptive Technology Fund Team: From left, Ray Hughes, Peter Landy, Conrad Noltey, Michael Hutchson, Jonathan Elliott, Michael Nolan, Noel O Loughlin.

Schivo is looking forward to working with its partners, Graph Engineering, Stryker Orthopaedics, SEAM & CREST gateway centres along with the services of Orthopaedic and Trauma Consultant Surgeon, Mr Benny Anto Padinjarathala, from University Hospital Waterford.

Founded in 1973, Schivo has a long-standing history of providing device development and manufacturing services for medical device companies from their facilities in Waterford. The company serves a diverse range of markets within the medical sector including Minimally Invasive Surgery, Orthopaedics, Cardiovascular/ Structural Heart, Neuro Surgery, ENT, Maxillofacial and Analytical Life sciences systems. Schivo support

customers device and analytic systems needs from prototyping, design for manufacturing through product development, product transfers, volume manufacturing, design for Assembly and full product builds. Schivo has many years experience in the orthopaedic sphere providing solutions for surgical tools as well as upper and lower limb implants.

Here are some intriguing stats on the orthopaedic industry:

  • The UK national joint registry reported that uncemented (coated) prostheses are continuing to increase in frequency and are now the most frequently implanted primary hip replacements. 91,698 hip replacements were preformed in the UK in 2017. (Source: The National Joint Register 15th Annual Report 2017)
  • The global orthopedic device market size is expected to reach USD 47.7 billion by 2026, according to the study performed by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.1% over the forecast period. (Source: Grandview Research,2018)
Recent Posts

Start typing and press Enter to search

An image of four Schivo employees stepping-into-2019 wearing festive Christmas jumpers.